ChemoCentryx Shares Rise After Unexpected FDA Approval
[ad_1] Text size The FDA released critical briefing papers on the avacopan study data in May. Dreamstime.com Biotechnology stocks ChemoCentryx are up more than 60% on Friday after the Food and Drug Administration surprised investors by approving the company’s drug avacopan as a treatment for a rare condition called ANCA-associated vasculitis. Investors had all but … Read more